Prostate cancer, the most frequently diagnosed cancer in Western men, can display a high variability in term of clinical aggressiveness and prognosis and none of the available markers is able to accurately predict its clinical course. Dystroglycan (DG), a non-integrin adhesion molecule, is a complex formed by two subunits, alpha- and beta-DG, which bind to extracellular matrix molecules and cytoskeleton, respectively. DG expression is frequently reduced in human cancers and has been related to tumor grade and aggressiveness. This study investigated the role of DG in human prostate tumorigenesis and its suitability as a prognostic marker. The expression level of extracellular alpha-DG subunit was frequently reduced in human prostate cancer cell lines and primary tumors and the percentage of positive tumor cells was significantly further decreased in vivo following androgen ablation therapy (median = 1%) compared to pre-treatment samples (median = 28%). A significant relationship was observed between alpha-DG staining on the post-treatment samples and tumor recurrence. A dose- and time-dependent decrease of DG expression also occurred in human prostate cancer cells following treatment with the anti-androgen flutamide. Stable expression of an exogenous DG cDNA in the LNCaP human prostate carcinoma cell line resulted in a marked inhibition of both anchorage-dependent and independent growth and of the in vivo tumorigenicity. These findings confirm and extend previous evidence that disturbances in the function of the DG complex might contribute to the definition of the malignant behavior of prostate cancer cells and suggest that androgens might regulate DG expression in these cells.

Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells / A., Sgambato; B., DE PAOLA; Migaldi, Mario; M., DI SALVATORE; A., Rettino; G., Rossi; B., Faraglia; A., Boninsegna; Maiorana, Antonino; A., Cittadini. - In: JOURNAL OF CELLULAR PHYSIOLOGY. - ISSN 0021-9541. - STAMPA. - 213:2(2007), pp. 528-539. [10.1002/jcp.21130]

Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells.

MIGALDI, Mario;MAIORANA, Antonino;
2007

Abstract

Prostate cancer, the most frequently diagnosed cancer in Western men, can display a high variability in term of clinical aggressiveness and prognosis and none of the available markers is able to accurately predict its clinical course. Dystroglycan (DG), a non-integrin adhesion molecule, is a complex formed by two subunits, alpha- and beta-DG, which bind to extracellular matrix molecules and cytoskeleton, respectively. DG expression is frequently reduced in human cancers and has been related to tumor grade and aggressiveness. This study investigated the role of DG in human prostate tumorigenesis and its suitability as a prognostic marker. The expression level of extracellular alpha-DG subunit was frequently reduced in human prostate cancer cell lines and primary tumors and the percentage of positive tumor cells was significantly further decreased in vivo following androgen ablation therapy (median = 1%) compared to pre-treatment samples (median = 28%). A significant relationship was observed between alpha-DG staining on the post-treatment samples and tumor recurrence. A dose- and time-dependent decrease of DG expression also occurred in human prostate cancer cells following treatment with the anti-androgen flutamide. Stable expression of an exogenous DG cDNA in the LNCaP human prostate carcinoma cell line resulted in a marked inhibition of both anchorage-dependent and independent growth and of the in vivo tumorigenicity. These findings confirm and extend previous evidence that disturbances in the function of the DG complex might contribute to the definition of the malignant behavior of prostate cancer cells and suggest that androgens might regulate DG expression in these cells.
213
2
528
539
Dystroglycan expression is reduced during prostate tumorigenesis and is regulated by androgens in prostate cancer cells / A., Sgambato; B., DE PAOLA; Migaldi, Mario; M., DI SALVATORE; A., Rettino; G., Rossi; B., Faraglia; A., Boninsegna; Maiorana, Antonino; A., Cittadini. - In: JOURNAL OF CELLULAR PHYSIOLOGY. - ISSN 0021-9541. - STAMPA. - 213:2(2007), pp. 528-539. [10.1002/jcp.21130]
A., Sgambato; B., DE PAOLA; Migaldi, Mario; M., DI SALVATORE; A., Rettino; G., Rossi; B., Faraglia; A., Boninsegna; Maiorana, Antonino; A., Cittadini
File in questo prodotto:
File Dimensione Formato  
Dystroglycan.pdf

non disponibili

Tipologia: Post-print dell'autore (bozza post referaggio)
Dimensione 479.87 kB
Formato Adobe PDF
479.87 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/310506
Citazioni
  • ???jsp.display-item.citation.pmc??? 12
  • Scopus 45
  • ???jsp.display-item.citation.isi??? 42
social impact